23andMe's journey from a $6B valuation to penny stock status is a cautionary tale of speculative investing. WSJ explores what went wrong, highlighting the risks involved in betting on such high-risk stocks. With bankruptcy looming, 23andMe's strategy and stock performance are under scrutiny. Investors should proceed with caution.